As Biotechnology businesses, Tyme Technologies Inc. (NASDAQ:TYME) and Forty Seven Inc. (NASDAQ:FTSV), are affected by contrast. This especially applies to their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyme Technologies Inc.	N/A	0.00	27.10M	-0.27	0.00
Forty Seven Inc.	N/A	0.00	70.37M	-2.06	0.00

In table 1 we can see Tyme Technologies Inc. and Forty Seven Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows Tyme Technologies Inc. and Forty Seven Inc.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tyme Technologies Inc.	0.00%	-127.5%	-109.1%
Forty Seven Inc.	0.00%	0%	0%

Liquidity

The Current Ratio and Quick Ratio of Tyme Technologies Inc. are 5.1 and 5.1 respectively. Its competitor Forty Seven Inc.’s Current Ratio is 11.9 and its Quick Ratio is 11.9. Forty Seven Inc. can pay off short and long-term obligations better than Tyme Technologies Inc.

Insider & Institutional Ownership

Tyme Technologies Inc. and Forty Seven Inc. has shares held by institutional investors as follows: 16.3% and 67.3%. Tyme Technologies Inc.’s share held by insiders are 0.1%. Competitively, insiders own roughly 5.1% of Forty Seven Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Tyme Technologies Inc.	-10.31%	-12.64%	-26.56%	5.86%	-15.16%	-36.31%
Forty Seven Inc.	1.35%	17.43%	-6.15%	12.09%	0%	9.73%

For the past year Tyme Technologies Inc. has -36.31% weaker performance while Forty Seven Inc. has 9.73% stronger performance.

Summary

On 4 of the 6 factors Forty Seven Inc. beats Tyme Technologies Inc.

Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.